Global Radiopharmaceuticals Market is Growing at a Significant Rate in the Forecast Period 2018-2025

Global Radiopharmaceuticals Market According to Data Bridge Market Research new Market report, “By Type (Diagnostic, Therapeutic Radiopharmaceuticals), By Procedural Volumes(Diagnostic Procedures, Therapeutic Procedures), By Application(Diagnostic Application{Single-Photon Emission Computed Tomography,  Positron Emission Tomography}, Therapeutic Application{Thyroid, Bone Metastasis, Lymphoma, Endocrine Tumors, Others}), By Sources (Nuclear Reactors , Cyclotrons), By End-User(Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Cancer Research Institutes, Others), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends and Forecast is projected to reach USD 10.57 billion by 2025, at a CAGR of 9.0% during the forecast period of 2018 to 2025.

Access Full Report:

Global Radiopharmaceuticals Market

Radiopharmaceuticals are the drugs that can be used for either diagnostic or therapeutic purpose. This are administered to the patient and are monitored through specific imaging devices. Radiopharmaceuticals are also used in bone pain. They have preferential uptake into bone. Phosphorous 32 was the compound which was used in treating pain from bony metastases. Other radiopharmaceuticals use for this purpose are strontium-89 and samarium-153, which are commercially available in U.S. Earlier the conventional chemotherapy methods were used but now this methods have been replace by  radiopharmaceuticals  for cancer treatment. In diagnosis and evaluation of the prostate cancer  Gallium 68 has played a very important role.

According to the guide to the nuclear wallchart around 30 million peoples are hospitalize each year. Out of which one third are treated with nuclear medicine, that is more than 10 million nuclear medicine procedure are performed and more than 100 million of nuclear medicine tests are performed  each year. Today there  are almost 100 isotopes used in diagnosis and therapy.

In the treatment of glioblastoma multiform, which a type of brain cancer affects 12,500 peoples in U.S.. It is almost impossible to treat by currently available means. Hence a new method was invented to extend the life of the patient suffering from this, that is Brachytherapy, this involves the use of radioactive isotopes. It delivers ionizing radiations directly into the tumor bed. According to PubMed database, in 2015 a study was conducted that includes 1571 patients who was given brachytherapy. And it was found that the longest median overall survival reach  to  28.5 months. And for the patients in which glioblastoma multiforme reoccur , the longest reported median overall survival was 15.9 months. This shows that the use radiopharmaceuticals can extend the life patient suffering from cancer or glioblastoma multiforme.

Market Segmentation: Global Radiopharmaceuticals Market

The global market for radiopharmaceuticals by the following sub-categories is presented

  • By Type

    • Diagnostic
    • Therapeutic Radiopharmaceuticals

  • By Procedural Volume

    • Diagnostic Procedures

      • Single-Photon Emission Computed Tomography Radiopharmaceuticals
      • Positron Emission Tomography Radiopharmaceuticals

    • Therapeutic Procedures

      • Beta Emitters
      • Alpha Emitters
      • Brachy Therapy

  • By Application

    • Diagnostic Application

      • Single-Photon Emission Computed Tomography

        • Cardiology
        • Lymphoma
        • Thyroid
        • Neurology
        • Others

      • Positron Emission Tomography

        • Oncology
        • Cardiology
        • Neurology
        • Others

    • Therapeutic Application

      • Thyroid
      • Bone Metastasis
      • Lymphoma
      • Endocrine Tumors
      • Others

  • By Sources

    • Nuclear Reactors
    • Cyclotrons

  • By End User

    • Hospitals
    • Ambulatory Surgical Centers
    • Diagnostic Centers
    • Cancer Research Institutes
    • Others

  • By Geography

    • North America
    • South America
    • Europe
    • Asia-Pacific
    • Middle East and Africa


Increasing incidence of cancer and cardiac ailments:

According to world health organization cancer was responsible for around 8.8million deaths in 2015. It was found that globally 1in 6 deaths is due to cancer. Low income and middle income country is responsible for around 70.0% of total deaths from cancer. 22.0% of cancer deaths is due to the use of tobacco. Hepatitis and human papilloma virus (HPV) are responsible for around 25.0% of cancer cases in low and middle income countries. Treatment was available for more than 90.0% of the high income countries. Lung cancer is responsible for 1.69 million deaths. Liver cancer is responsible for 788,000 deaths, breast cancer is responsible for 571,000 deaths.

According to the national cancer institute 1,735,350 new cases of cancer will be diagnosed in the United States. Based on the 2011-2015 data the number of cases of cancer is 164 per 1000,000 persons. Cancer mortality is higher in men that are 197 per 100,000 men and in women it is 139 per 100,000 women.

According to the international agency for research on cancer there were 14.1 million new cases of cancer in 2012 and it is expected to rise every year that is it is expected to grow to 23.6 million by 2030.

As radio pharmaceuticals are used to treat life threatening disease such as cancer. It is also found that there is fall in death rate by cancer by the use of radiopharmaceuticals. Hence as per the data provided above, the number of case of cancers are expected to increase in future, hence with hike in the cancer patients there will be hike in use of radiopharmaceuticals too, as radio pharmaceuticals are used in the treatment and diagnosis  of cancer. Hence this market is expected to grow in future.

Advances in radiotracers and alpha radio immunotherapy-based targeted cancer treatment:

Radioisotopes therapy delivers the radiation directly in to the cancer cells. Radioisotopes are usually given as a capsule, drink or by injecting into the veins. Cancer cells absorb the radioactive substance more than the normal cells hence they receive the higher dose and this leads the cell to die. Depending on what type of cancer, different types of radioisotopes are used. Iodine 131 is used in thyroid cancer and in some rare cancer. Strontium-89 and samarium-153 is used in secondary bone cancer, they helps in reducing pain. Radium-223 is used to treat secondary bone cancer, and this is the new isotope therapy.

Including positron emission tomography (PET) and single photon emission computed tomography (SPECT) is included in molecular radiotracer imaging. This has the tremendous potential in diagnosis of the brain changes. An injection of radiolabeled compound is injected and goes through the regional distribution of the brain can be visualize 3dimentionally by PET or SPECT.

Radio tracers are mostly used in human epilepsy. According to world nuclear association each year 40million of nuclear medicine procedures are performed. And the demand for radioisotopes is increasing by 5.0% annually. Around 10,000 hospitals use radioisotopes in medicines out of which 90.0% of radioisotopes is used for diagnosis. Technetium-99 is the most common radioisotope used with 40million procedures per month accounting for 80.0% of all nuclear medicine procedures worldwide.

 According to World health organization 50 million of the peoples have epilepsy and nearly 80.0% of the people with epilepsy lives in low and middle income country.

According to national health survey and national survey for children health in 2014 the rate of epilepsy was 2.3 million in 2014 and that increases to 3 million by 2015. And in 2007 number of children suffering from epilepsy was 450,000 and that increases to 470,000 by 2015.

As per the data provided, the number of cases of cancer and epilepsy are expected to increase at a very higher rate, this means the use for radioisotopes as well as the radiotracers will be increased. This shows that the radiopharmaceuticals market will have a strong growing platform in future.

Some of the major market players in the global radiopharmaceuticals market are Cardinal Health., Mallinckrodt, General Electric Company, Lantheus Medical Imaging, Inc, Bayer AG, Bracco Imaging S.p.A, Nordion Inc., IBA, Jubilant Pharma. LLC, Modus Medical Devices Inc, Actinium Pharmaceuticals, Inc., Areva Pharma, Merck & Co., Inc, Navidea Biopharmaceuticals, Inc., Siemens Healthcare Private Limited, Eckert & Ziegler, Avid Bioservices, Inc, Alseres Pharmaceuticals, Inc, Alliance Medical Diagnostic Imaging Ltd.

Browse Related Reports:

Global Cancer Biomarkers Market, By Tumor (Breast, Lung, Prostate), By Type (Protein Biomarker, Genetic Biomarkers), By Profiling Technology (Proteomics, Genomics, Imaging, Immunoassay), By Application (Diagnostic, Drug Discovery, Prognostic), By Geography (North America, Europe, Asia-Pacific, South America, Rest of the World) – Industry Trends and Forecast to 2024.

Europe Fetal Bovine Serum Market, By Product type, By End-User, By Distribution Channel, By Country (Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzeland, Rest Of Europe) – Industry Trends and Forecast to 2024.

Global Diabetes Care Devices Market,By Product Type (Blood glucose monitoring devices (testing strips, self-monitoring blood glucose meters, lancets, continuous glucose monitors, and others), Insulin drug delivery devices (insulin syringes, insulin pens, insulin pumps, and insulin jet injectors), By End-Users (Hospitals, Clinics, Home Healthcare, Ambulatory care, Others), By Geography (North America, Europe, Asia-Pacific, Europe, South America, Middle East and Africa)- Industry Trends and Forecast to 2024.

North America Contraceptive Devices Market, By Product Type, By End-User, By Distribution Channel, By Country ( U.S., Canada, Mexico) – Industry Trends and Forecast to 2024.